|
SLC7A6OS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.45910016980633E-14 |
| Normal-vs-Stage2 |
4.44250000009028E-07 |
| Normal-vs-Stage3 |
1.26298971281358E-12 |
| Normal-vs-Stage4 |
2.09132711148641E-12 |
| Stage1-vs-Stage2 |
6.996400E-01 |
| Stage1-vs-Stage3 |
5.889700E-02 |
| Stage1-vs-Stage4 |
2.225500E-02 |
| Stage2-vs-Stage3 |
1.351650E-01 |
| Stage2-vs-Stage4 |
3.902000E-02 |
| Stage3-vs-Stage4 |
4.701200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.88498130835069E-15 |
| Normal-vs-AfricanAmerican |
7.43049999973877E-07 |
| Normal-vs-Asian |
1.50540000465327E-08 |
| Caucasian-vs-AfricanAmerican |
8.523400E-01 |
| Caucasian-vs-Asian |
9.339400E-01 |
| AfricanAmerican-vs-Asian |
8.252800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.9190872769268E-14 |
| Normal-vs-Female |
1.63358215843346E-12 |
| Male-vs-Female |
2.884400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.96154203990773E-12 |
| Normal-vs-Age(41-60Yrs) |
1.1785017406396E-12 |
| Normal-vs-Age(61-80Yrs) |
6.39988062545171E-12 |
| Normal-vs-Age(81-100Yrs) |
1.764120E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.152200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.887000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.048400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.220600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.256400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.034400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.622230E-02 |
| Classical-VS-Follicular |
9.254800E-01 |
| Classical-VS-Other |
8.766200E-01 |
| Classical-VS-Normal |
1.62569957495862E-12 |
| Tall-VS-Follicular |
5.787500E-02 |
| Tall-VS-Other |
4.875600E-01 |
| Tall-VS-Normal |
3.48510109660083E-12 |
| Follicular-VS-Other |
8.695600E-01 |
| Follicular-VS-Normal |
3.58649999698812E-08 |
| Other-VS-Normal |
1.536260E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.4920954189156E-11 |
| Normal-vs-N1 |
1.9417800700694E-13 |
| N0-vs-N1 |
1.384440E-03 |
|
|
